600873 梅花生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.13421.22019.07222.98536.432
总资产报酬率 ROA (%)2.51213.19611.67013.35219.381
投入资产回报率 ROIC (%)2.90814.99813.28415.31822.413

边际利润分析
销售毛利率 (%)12.93018.99820.07519.68125.133
营业利润率 (%)6.69212.01713.92713.73718.471
息税前利润/营业总收入 (%)7.22515.42312.89313.29118.744
净利润/营业总收入 (%)5.41013.55210.93111.45915.772

收益指标分析
经营活动净收益/利润总额(%)75.89769.84195.73796.74696.008
价值变动净收益/利润总额(%)9.5432.4311.344-0.8191.107
营业外收支净额/利润总额(%)1.40022.003-4.234-2.424-0.143

偿债能力分析
流动比率 (X)1.2241.3341.1961.4561.486
速动比率 (X)0.7700.9180.8301.0090.876
资产负债率 (%)41.49536.92138.78538.84044.813
带息债务/全部投入资本 (%)29.13026.89427.98328.28733.076
股东权益/带息债务 (%)237.680265.552249.687245.454193.365
股东权益/负债合计 (%)140.995170.849157.830157.469123.151
利息保障倍数 (X)16.493932.365-27.563-110.38262.433

营运能力分析
应收账款周转天数 (天)9.0238.6648.8256.3674.004
存货周转天数 (天)59.28852.72550.71056.43760.763